P-glycoprotein efflux transporter activity often displays biphasic dose-response relationships

Critical Reviews in Toxicology

Volumn 38, Issue 5, 2008, Pages 473-487

  Calabrese, Edward J ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

Bioavailability; Biphasic; Blood Brain Barrier; Chemotherapy; Dose Response; Drug Resistance; Efflux Transporter Activity; Hormesis; P Glycoprotein; Tamoxifen; U shaped

Indexed keywords

GLYCOPROTEIN P;

BIOLOGICAL MODEL; BLOOD BRAIN BARRIER; CELL STIMULATION; CENTRAL NERVOUS SYSTEM; CHEMICAL MODEL; CONCENTRATION RESPONSE; HORMESIS; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PROTEIN FUNCTION; PROTEIN TRANSPORT; REVIEW;

ANIMALS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; HUMANS; P-GLYCOPROTEIN; PHARMACEUTICAL PREPARATIONS;

EID: 45849128319     PISSN: 10408444     EISSN: 15476898     Source Type: Journal    
DOI: 10.1080/10408440802004049     Document Type: Review

References (31)

1. Achard, M., Baudrimont, M., Boudou, A., and Bourdineaud, J.P. (2004). Induction of a multixenobiotic resistance protein (MXR) in the Asiatic clam Corbicula fluminea after heavy metals exposure. Aquatic Toxicol. 67:347-357.
2. Ambudkar, S.V., Lelong, I.H., Zhang, J., Cardarelli, C.O., Gottesman, M.M., and Pastan, I. (1992). Partial purification and reconstitution of the human multidrug-resistance pump: Characterization of the drug-stimulatable ATP hydrolysis. Proc. Natl. Acad. Sci. USA 89:8472-8476.
3. Calabrese, E.J., and Baldwin, L.A. (2001). Hormesis: U-shaped dose responses and their centrality in toxicology. Trend Pharm. Sci. 22:285-291.
4. Calabrese, E.J., and Blain, R. (2005). The occurrence of hormetic dose responses in the toxicological literature, the hormesis database: an overview. Toxicol. Appl. Pharmacol., 202:289-301.
5. Calabrese, E.J., Bachmann, K.A., Bailer, A.J., Bolger, P.M., Borak, J., Cai, L., Cedergreen, N., Cherian, M.G., Chiueh, C.C., Clarkson, T.W., et al. (2007). Biological stress response terminology: Integrating the concepts of adaptive response and preconditioning stress within a hormetic dose-response framework. Toxicol. Appl. Pharmacol., 222:122-128.
6. Darvari, R., and Boroujerdi, M. (2004). Concentration dependency of modulatory effect of amlodipine on P-glycoprotein efflux activity of doxorubicin - A comparison with tamoxifen. J. Pharm. Pharmacol. 56:985-991.
7. Dey, S., Ramachandra, M., Pastan, I., Gottesman, M.M., and Ambudkar, S.V. (1997). Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc. Natl. Acad. Sci. USA 94:10594-10599.
8. Didziapetris, R., Japertas, P., Avdeef, A., and Petrauskas, A. (2003). Classification analysis of P-glycoprotein substrate specificity. J. Drug Target. 11:391-406.
9. Doige, C.A., Yu, Z., and Sharom, F.J. (1993). The effects of lipids and detergents on ATPase-active P-glycoprotein. Biochmica et Biophysica Acta 1146:65-72 .
10. Doige, C.A., Yu, X., and Sharom, F.J. (1992). ATPase activity of partially purified P-glycoprotein from multidrug-resistant Chinese hamster ovary cells. Biochim. Biophys. Acta 1109:149-160.
11. Garrigues, A., Nugier, J., Orlowski, S., and Ezan, E. (2002). A high-throughput screening microplate test for the interaction of drugs with P-glycoprotein. Anal. Biochem. 305:106-114.
12. Gottesman, M.M., Pastan, I., and Ambudkar, S.V. (1996). Pglycoprotein and multidrug resistance. Curr. Opin. Gen. Dev. 6:610-617.
13. Hansen, N.T., Till, J.E., and Ling, V. (1976). Pleiotropic phenotype of colchicine-resistant CHO cells - Cross-resistance and collateral sensitivity. J. Cell. Physiol. 88:23-32.
14. Juliano, R.L., and Ling, V. (1976). A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455:152-162.
15. Kim, R.B., Fromm, M.F., Wandel, C., Leake, B., Wood, A.J., Roden, D.M., and Wilkinson, G.R. (1998). The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101:289-294.
16. Ling, V. (1975). Drug-resistance and membrane alteration in mutants of mammalian cells. Can. J. Genet. Cytol. 17:503-515.
17. Ling, V., and Thompson, L.H. (1974). Reduced permeability in CHOcells as a mechanism of resistance to colchicine. J. Cell. Physiol. 83:103-116.
18. Litman, T., Zeuthen, T., Skovsgaard, T., and Stein, W.D. (1997). Structure-activity relationships of P-glycoprotein interacting drugs: Kinetic characterization of their effects on ATPase activity. Biochim. Biphys. Acta 1361:159-168.
19. Lown, K.S., Mayo, R.R., Leichtman, A.B., Hsiao, H.L., Turgeon, D.K., Schmiedlin-Ren, P., Brown, M.B., Guo,W., Rossi, S.J., Benet, L.Z., and Watkins, P.B. (1997). Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. 62:248-260.
20. Polli, J.W., Jarrett, J.L., Studenberg, S.D., Humphreys, J.E., Dennis, S.W., Brouwer, K.R., and Woolley, J.L. (1999). Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), and HIV protease inhibitor. Pharm. Res. 16:1206-1212.
21. Romsicki, Y., and Sharom, F.J. (1999). The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter. Biochemistry 38:6887-6896.
22. Sarkadi, B., Price, E.M., Boucher, R.C., Germann, U.A., and Scarborough, G.A. (1992). Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J. Biol. Chem. 267:4854-4858.
23. Schmid, D., Ecker, G., Kopp, S., Hitzler, M., and Chiba, P. (1999). Structure-activity relationship studies of propafenone analogs based on P-glycoprotein ATPase activity measurements. Biochem. Pharmacol. 58:1447-1456.
24. Schwarz, U.I., Gramatte, T., Krappweis, J., Oertel, R., and Kirch, W. (2000). P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int. J. Clin. Pharmacol. Ther. 38:161-167.
25. Shapiro, A.B., and Ling, V. (1994). ATPase activity of purified and reconstituted P-glycoprotein from Chinese hamster ovary cells. Biol. Chem. 269:3745-3754.
26. Sharom, F.J., Yu, X., and Doige, C.A. (1993). Functional reconstitution of drug transport and ATPase activity in proteoliposomes containing partially purified P-glycoprotein. J. Biol. Chem. 268:24197-24202.
27. Shepard, R.L., Winter, M.A., Hsaio, S.C., Pearce, H.L., Beck,W.T., and Dantzig, A.H. (1998). Effect of modulators on the ATPase activity and vanadate nucleotide trapping of human P-glycoprotein. Biochem. Pharmacol. 56:719-727.
28. Sparreboom, A., van Asperen, J., Mayer, U., Schinkel, A.H., Smit, J.W., Meijer, D.K., Borst, P., Nooijen, W.J., Beijnen, J.H., and van Tellingen, O. (1997). Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA 94:2031-2035.
29. Szabadi, E. (1977). Model of 2 functionally antagonistic receptor populations activated by same agonist. J. Theor. Biol. 69:101-112.
30. Urbatsch, I.L., Al-Shawi, M.K., and Senior, A.E. (1994). Characterization of the ATPase activity of purified Chinese hamster Pglycoprotein. Biochemistry 33:7069-7076.
31. Verschraagen, M., Koks, C.H., Schellens, J.H., and Beijnen, J.H. (1999). P-glycoprotein system as a determinant of drug interactions: The case of digoxin-verapamil. Pharmacol. Res. 40:301-306.